Yiwu Huang, MD
Hematology & Oncology · Brooklyn, NYNPI 1780798462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,793 of the $219,911 with a category attached, or 72.2%. 48 manufacturers reported payments, led by AstraZeneca at 54.1% of the total. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 820 payments — averaging $268.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$119K
- Rigel Pharmaceuticals, Inc.$25K
- Exelixis Inc.$22K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Eisai Inc.$7K
- Daiichi Sankyo Inc.$6K
- plus $24K from 42 others
Across 45 payments — averaging $300.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$12K
- Daiichi Sankyo Inc.$1K
What the payments were for
- Consulting fees$28,94013%
- Speaking & faculty fees$158,79372%
- Travel & lodging$10,8165%
- Food & beverage$20,6039%
- Education$7590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,911 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 75 | $1,356,027 |
| PromactaEltrombopag Olamine | 23 | $943,564 |
| BrukinsaZanubrutinib | 35 | $573,433 |
| QinlockRipretinib | 12 | $494,955 |
| WeliregBelzutifan | 13 | $401,034 |
| Lenalidomide | 30 | $340,301 |
| IbrancePalbociclib | 27 | $339,671 |
| FruzaqlaFruquintinib | 11 | $269,897 |
| AlecensaAlectinib Hcl | 24 | $259,933 |
| LenvimaLenvatinib Mesylate | 11 | $246,530 |
| XalkoriCrizotinib | 11 | $228,101 |
| VerzenioAbemaciclib | 26 | $179,045 |
| NinlaroIxazomib Citrate | 11 | $145,565 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $129,011 |
| TasignaNilotinib Hcl | 13 | $115,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $119,016 | $1,356,02775 claims |
| NovartisPromacta, Tasigna | $711 | $1,059,36236 claims |
| PfizerIbrance, Xalkori, Eliquis | $124 | $592,35076 claims |
| Beigene USA, Inc.Brukinsa | $525 | $573,43335 claims |
| Deciphera Pharmaceuticals Inc.Qinlock | $82 | $494,95512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla, Ninlaro | $17,603 | $415,46222 claims |
| MerckWelireg | $829 | $401,03413 claims |
| Genentech USA, Inc.Alecensa | $2,977 | $259,93324 claims |
| Eisai Inc.Lenvima | $6,823 | $246,53011 claims |
| Lilly USA, LLCVerzenio | $361 | $179,04526 claims |
| Taiho Oncology, Inc.Lonsurf | $159 | $129,01114 claims |
| AbbVieCreon | $48 | $24,32417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Brooklyn
- Perry CookBrooklyn$803K
- Ilya BlokhBrooklyn$220K
- Songchuan GuoBrooklyn$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.